Aligos Therapeutics Net Profit Margin Growth & History (ALGS)
Aligos Therapeutics's net profit margin was −1,106.72% for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,106.72% | +2526.92 pp |
| 2024 | 2024-12-31 | −3,633.65% | −2217.41 pp |
| 2023 | 2023-12-31 | −1,416.23% | — |
Aligos Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −814.13% | −14668.80 pp |
| Q4 2025 | 2025-12-31 | −11,763.91% | +1792.20 pp |
| Q3 2025 | 2025-09-30 | −4,256.01% | −2715.29 pp |
| Q2 2025 | 2025-06-30 | −1,643.83% | −2120.84 pp |
| Q1 2025 | 2025-03-31 | 13,854.66% | +18878.15 pp |
| Q4 2024 | 2024-12-31 | −13,556.11% | −9405.51 pp |
| Q3 2024 | 2024-09-30 | −1,540.72% | +122.04 pp |
| Q2 2024 | 2024-06-30 | 477.00% | +914.61 pp |
| Q1 2024 | 2024-03-31 | −5,023.49% | +11372.94 pp |
| Q4 2023 | 2023-12-31 | −4,150.60% | — |
| Q3 2023 | 2023-09-30 | −1,662.76% | — |
| Q2 2023 | 2023-06-30 | −437.61% | — |
| Q1 2023 | 2023-03-31 | −16,396.43% | — |
Aligos Therapeutics net profit margin trends
Between the periods ended 2023-12-31 and 2025-12-31, Aligos Therapeutics's net profit margin increased from −1,416.23% to −1,106.72%, a change of +309.51 percentage points. The latest reported quarter, Q1 2026, shows −814.13%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗